articleNew England Journal of MedicineNov 9, 2013Closed access

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

University of Pittsburgh · VA Pittsburgh Healthcare System · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a…

Citation impact

1,171
total citations
FWCI
73.62
Percentile
100%
References
19
Citations per year

Authors

16

Topics & keywords

Keywords
  • Medicine
  • Diabetic nephropathy
  • Nephropathy
  • Angiotensin II
  • Diabetes mellitus
  • Internal medicine
  • Renin–angiotensin system
  • Pharmacology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.